Publication details

Zhodnocení účinnosti a rizik v léčbě roztroušené sklerózy

Title in English Evaluation of efficacy and risks in the treatment of multiple sclerosis
Authors

ŠTOURAČ Pavel

Year of publication 2017
Type Article in Periodical
Magazine / Source Klinická farmakologie a farmacie
MU Faculty or unit

Faculty of Medicine

Citation
Field Neurology, neurosurgery, neurosciences
Keywords treatment of multiple sclerosis; efficacy; risks
Description We use for the treatment of relapsing-remitting course of multiple sclerosis the drugs with different mechanisms of action anddifferent clinical efficacy and safety profile. The treatment algorithm involves current clinical status of the patient and long-termefficacy and safety of the drug. The available drugs are as following; interferon beta-1a (IFNbeta-1a), interferon beta-1b (IFNbeta-1b),glatiramer acetate(GA), teriflunomide, dimethylfumarate, fingolimode, natalizumab and alemtuzumab.

You are running an old browser version. We recommend updating your browser to its latest version.

More info